Endofotonics logo — Identifying Early-stage Cancers Through In vivo Molecular Di...

Endofotonics

Identifying Early-stage Cancers Through In vivo Molecular Diagnosis

Founded 2013 Singapore Singapore 4 employees Series B Total: $9.06M Biotechnology, Health Care +1

General Information

Company Name Endofotonics
Founded Year 2013
Location Singapore Singapore +1
Employees 4
Industries Biotechnology, Health Care, Information Technology
Funding Stage Series B
Social

Get notified when Endofotonics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Endofotonics

Endofotonics is a medtech organisation dedicated to using its proprietary Raman spectroscopy platform technology to improve early cancer detection and reduce cancer burden in patients. Founded in 2013 and headquartered in Singapore with a subsidiary in Shanghai, China, the company developed the SPECTRA IMDx™ system, the world's first real-time in-vivo Raman spectroscopy platform, that improves early gastric cancer detection rate. The company is currently helmed by a lean team of highly skilled and specialized engineers and PhD executives in various fields such as optics, biomedical, academic research, and industrial product development. Endofotonics has received $12 million in Series B funding, led by Beng Teck Liang and Tony Tan Choon Keat in May 29th, 2020. This funding will support the commercialization of the SPECTRA IMDx in the Asia Pacific and beyond. For more information, please visit www.endofotonics.com or email your enquiries to [email protected]. Follow and like them on facebook.com/endofotonics.

Taxonomy: Medtech, Raman spectroscopy, Cancer detection, In-vivo diagnosis, Gastric cancer, Early-stage detection, Biomedical technology, Optics, Medical devices, Advanced manufacturing, Endoscopy, Spectroscopy platform, Series B funding, Asia Pacific commercialization, Lean team

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 2 •••• •••• 29 May 2020
Series A •••••• 2
Investor Investor
01 Jan 2016
Angel Round •••••• - 01 Apr 2014

Endofotonics Alternatives & Competitors

Endofotonics vs

The Future of Cancer Diagnostics

Series A
24 employees
Biotechnology, Health Care
Endofotonics vs

Pioneering non-invasive skin cancer detection with advanced infrared laser and AI technology

Series Unknown
11-50 employees
Biotechnology, Health Care
Endofotonics vs

O-PTIR: Sub-micron IR multimodal spectroscopy, simultaneous IR+Raman, Widefield O-PTIR and simultane...

18 employees
Industrial, Manufacturing

FAQ About Endofotonics

Identifying Early-stage Cancers Through In vivo Molecular Diagnosis
Endofotonics was founded in 2013.
Endofotonics is headquartered in Singapore.
Endofotonics operates in the following industries: Biotechnology, Health Care, Information Technology.
Endofotonics has approximately 4 employees.
Endofotonics has completed 3 funding rounds, raising a total of $9.06M. The latest funding stage is Series B.
Top alternatives and competitors to Endofotonics include Dxcover, Magnosco, Photothermal Spectroscopy Corp, AOA Dx, Previse. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Endofotonics and Dxcover are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Endofotonics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy